Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma
Delia D’Avola, Alessandro Granito, Manuel de la Torre‐Aláez, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 5, pp. 1185-1198
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

TKIs in combination with immunotherapy for hepatocellular carcinoma
Bernardo Stefanini, Luca Ielasi, Rusi Chen, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 3, pp. 279-291
Closed Access | Times Cited: 87
In vivo liver function reserve assessments in alcoholic liver disease by scalable photoacoustic imaging
Tong Sun, Jing Lv, Xingyang Zhao, et al.
Photoacoustics (2023) Vol. 34, pp. 100569-100569
Open Access | Times Cited: 59
Loss of liver function in chronic liver disease: An identity crisis
Carmen Berasain, María Arechederra, Josepmaria Argemì, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 2, pp. 401-414
Open Access | Times Cited: 55
Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function
Giuseppe Cabibbo, Alessio Aghemo, Quirino Lai, et al.
Digestive and Liver Disease (2022) Vol. 54, Iss. 4, pp. 452-460
Closed Access | Times Cited: 47
Immune Checkpoint Inhibitor in Hepatocellular Carcinoma: Response Rates, Adverse Events, and Predictors of Response
Shekhar Swaroop, Sagnik Biswas, Shubham Mehta, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 1034-1034
Open Access | Times Cited: 1
Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
Masatoshi Kudo, Richard S. Finn, Ann‐Lii Cheng, et al.
Liver Cancer (2023) Vol. 12, Iss. 5, pp. 479-493
Open Access | Times Cited: 19
Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience
Laihui Luo, Yongqiang Xiao, Guoqing Zhu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 25
Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
Laihui Luo, Yongzhu He, Guoqing Zhu, et al.
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 1353-1368
Open Access | Times Cited: 23
Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations
Jasem Albarrak, Humaid O. Al‐Shamsi
Cancers (2023) Vol. 15, Iss. 7, pp. 2001-2001
Open Access | Times Cited: 16
Contemporary applications of Y90 for the treatment of hepatocellular carcinoma
Qian Yu, Michael Khanjyan, Nicholas Fidelman, et al.
Hepatology Communications (2023) Vol. 7, Iss. 10
Open Access | Times Cited: 15
Transarterial Radioembolization (TARE) in Patients with Hepatocellular Carcinoma: A Comparison of Palliative with Bridging-to-Transplant Concepts
Jacqueline Schönherr, Philipp Seifert, Falk Gühne, et al.
Cancers (2024) Vol. 16, Iss. 1, pp. 235-235
Open Access | Times Cited: 5
Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care
Benedetta Stefanini, Laura Bucci, Valentina Santi, et al.
Digestive and Liver Disease (2024) Vol. 56, Iss. 9, pp. 1582-1591
Closed Access | Times Cited: 5
The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors
Zhen-Xin Zeng, Jiayi Wu, Junyi Wu, et al.
Hepatology International (2023) Vol. 18, Iss. 2, pp. 651-660
Closed Access | Times Cited: 11
Systemic Therapies for Hepatocellular Carcinoma in India
Vinay Jahagirdar, Kaanthi Rama, Mohammed F. Habeeb, et al.
Journal of Clinical and Experimental Hepatology (2024) Vol. 14, Iss. 6, pp. 101440-101440
Closed Access | Times Cited: 4
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion
Shuang‐Yan Tang, Feng Shi, Yi Xiao, et al.
Hepatology International (2025)
Closed Access
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
Atsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, et al.
Cancer Medicine (2025) Vol. 14, Iss. 2
Open Access
Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multicenter study
Qizhen Huang, Xiaohong Zhong, Shaoxing Chen, et al.
Hepatology International (2025)
Closed Access
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 671-683
Open Access
Hepatocellular Carcinoma: Surveillance, Diagnosis, Evaluation and Management
Jessica Elderkin, Najeeb Al Hallak, Asfar S. Azmi, et al.
Cancers (2023) Vol. 15, Iss. 21, pp. 5118-5118
Open Access | Times Cited: 10
Child–Pugh grade deterioration stratified by the etiology after transcatheter arterial chemoembolization as initial treatment for hepatocellular carcinoma
Kengo Yoshitomi, Tsuguru Hayashi, Shinji Oe, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy
Zehao Zheng, Jie Mei, Renguo Guan, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 8
Open Access | Times Cited: 3
Clinical Characteristics and Prognosis of Early-Onset Hepatocellular Carcinoma: A Retrospective Cohort Study Based on Population Data
Yufan Guan, Yu Gan, Jiaze An
Digestive Diseases and Sciences (2024) Vol. 69, Iss. 9, pp. 3563-3573
Closed Access | Times Cited: 3
Predictors of Complications in Radiofrequency Ablation for Hepatocellular Carcinoma: A Comprehensive Analysis of 1000 Cases
Mohamed Farag, Mohamed H. Shaaban, Hamdy Abdelkader, et al.
Medicina (2025) Vol. 61, Iss. 3, pp. 458-458
Open Access
Clinically Evident Portal Hypertension Is an Independent Risk Factor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation
A. Kornberg, Nick Seyfried, Helmut Frieß
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 2032-2032
Open Access
Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study
Minghao Xu, Cheng Huang, Mei‐Ling Li, et al.
Cancer Medicine (2023) Vol. 12, Iss. 8, pp. 9202-9212
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top